Healthcare Technology Report September 11, 2024
Merck, known as MSD outside the US and Canada, has announced a definitive agreement to acquire CN201, a promising bispecific antibody developed by Curon Biopharmaceutical. This transaction, valued at $700 million upfront, includes potential milestone payments up to $600 million. CN201, currently in...